Ametik

Ametik Uses, Dosage, Side Effects, Food Interaction and all others data.

Ametik is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

Ametik
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ametik
Availability	Prescription only
Generic	Trimethobenzamide
Trimethobenzamide Other Names	Trimethobenzamide, Trimethobenzamidum, Trimetobenzamida
Related Drugs	hydroxyzine, lorazepam, ondansetron, Zofran, meclizine, promethazine
Type
Formula	C₂₁H₂₈N₂O₅
Weight	Average: 388.4574 Monoisotopic: 388.199822016
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Turkey
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ametik is an antiemetic used to treat postoperative nausea and vomiting and nausea associated with gastroenteritis.

For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Ametik is also used to associated treatment for these conditions: Nausea, Nausea and vomiting

How Ametik works

The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited.

Toxicity

Oral LD₅₀ in mice is 1600 mg/kg.

Food Interaction

Avoid alcohol. Ingestion of alcohol may increase the CNS depressant effects of trimethobenzamide causing drowsiness.

[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.

Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.

Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.